NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study

BACKGROUND: Although oral and intravenous forms of idronoxil have been well tolerated, the safety of NOX66, with idronoxil formulated as a rectal suppository, is not known. This Phase Ia/b clinical study (protocol No. NOX66-001A), known as Chemotherapy Enhancement Program-1, is the first to assess N...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiknavelidze, Koba, Shavdia, Mikheil, Chikhladze, Nana, Abshilava, Lia, Messina, Marinella, Mautner, Gisela, Kelly, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296080/
https://www.ncbi.nlm.nih.gov/pubmed/34306271
http://dx.doi.org/10.1016/j.curtheres.2021.100631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296080/
https://www.ncbi.nlm.nih.gov/pubmed/34306271
http://dx.doi.org/10.1016/j.curtheres.2021.100631

Ejemplares similares